Potential Federal Drug Savings Could Propel Biosimilars Bill
Executive Summary
The potential for biosimilars to lower Medicare and Medicaid drug spending could help catalyze support for a follow-on biologics bill this year, a Capitol Hill staffer predicted at the Food and Drug Law Institute's annual conference March 26
You may also be interested in...
Canada Biosimilars Proposal Requires Extra Studies To Show Substitutability
Substitution of a biosimilar for its reference brand product would not be automatic under the framework proposed by Health Canada for approving what it calls "subsequent entry biologics.
Canada Biosimilars Proposal Requires Extra Studies To Show Substitutability
Substitution of a biosimilar for its reference brand product would not be automatic under the framework proposed by Health Canada for approving what it calls "subsequent entry biologics.
Biosimilars Bill From Reps. Eshoo, Barton Gathers Steam In House Cmte.
The counter-intuitive political dynamics of the follow-on biologics debate in the House Energy and Commerce Committee are on full display with the introduction of a bill from Rep. Anna Eshoo, D-Calif., and Joe Barton, R-Texas